Effect of Epidermal Growth Factor on Cell Survival of Human Ovarian Teratocarcinoma Cell Line

Epidermal Growth Factor가 난소 기형암종 배아세포주의 생존율에 미치는 효과

  • Kim, Chung-hui (College of Veterinary Medicine, Gyeongsang National University, Institute of Animal Medicine) ;
  • Kim, Jong-shu (College of Veterinary Medicine, Gyeongsang National University, Institute of Animal Medicine) ;
  • Cuong, Dang Van (Department of Physiology & Biophysics, College of Medicine, Inje University) ;
  • Kim, Na-ri (Department of Physiology & Biophysics, College of Medicine, Inje University) ;
  • Kim, Eui-yong (Department of Physiology & Biophysics, College of Medicine, Inje University) ;
  • Han, Jin (Department of Physiology & Biophysics, College of Medicine, Inje University)
  • 김충희 (경상대학교 수의과대학 동물의학연구소) ;
  • 김종수 (경상대학교 수의과대학 동물의학연구소) ;
  • ;
  • 김나리 (인제대학교 의과대학 생리학교실) ;
  • 김의용 (인제대학교 의과대학 생리학교실) ;
  • 한진 (인제대학교 의과대학 생리학교실)
  • Accepted : 2003.03.25
  • Published : 2003.06.30

Abstract

Human ovarian cancerous cells survive in a way that they trigger the nucleotide excision repair (NER) or double-strand DNA repair (dsDNA) repair mechanism to show resistance to anticancer drugs and activate many kinds of repair protein, thus removing damaged DNAs. Two experiments on the PA-1 human ovarian teratocareinoma cell line that hardly has any expression of epidermal growth factor receptor (EGFR) were conducted in the study; first, EGF-R was transfected and its receptor was obtained. The receptor was investigated in terms of its mutual relations with many kinds of protein concerning NER or dsDNA repair. Second, it was examined what kind impact cisplatin and adriamycin had on the effects of EGF-R over the PA-1 cell line lacking EGF-R. When being administered with cisplatin and adriamycin, Hey and Hey C2 cell lines showed a high level of resistance while PA-1 cell line a high level of sensitivity. Hey and Hey C2 cell lines that are resistant against anticancer drugs exhibited a high level of EGF-R expression while PA-1 cell line that is sensitive to them did a much lower level of the expression. When PA-1 cell line was transfected for the expression of DNA adduct and EGF-R, it showed a higher level of resistance compared to the control group. There was no difference in the expression of DNA repair proteins (DNA- dependent protein kinase, Ku70, and Ku80) between Hey and the PA-1 cell lines. The results indicate that the Hey cell line that is resistant against cisplatin and adriamycin works along the signaling system responding to the changes of EGF-R while the PA-1 cell line that is sensitive to both of them does to the lack of EGF-R.

References

  1. Leighton, C., Fisher, B., Bauman, G., Depiero, S., Stitt, L., Macdonald, D., and Cairncross G. Supratentorial low-grade gliomas in adults: an analysis of prognostic factors and timing of radiation. J. Clin. Oncol. 1997, 15, 1294-1301
  2. Elliott, T. E., Dinapoli, R P., O'Fallon, J. R., Krook, J. E., Earle, J. D., Morton, R. F., Levittt, R., Tschette, L. K., Scheithauer, B.W., Pfeifle, D. M., Twito, D. L, and Nelimark, R.A. Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma. J. Neurooncol. 1997, 33, 239-250
  3. Persons, D. L., Yazlovitskaya, E. M., Cui, W., and Pelling, J. C. Cisplatin-induced acdvation of mitogenactivated protein kinase in ovarian carcinoma cells: Inhibition of extracellular signal-regulated kinase activity increase sensitivity to cisplatin. Clin. Cancer Res. 1995, 5, 1007-1014
  4. Asagoshi, K., Yamada, T., Terato, H., Ohyama, Y., Monden, Y., Arai, T., Nishimura, S., Aburatani, H., Lindahl, T., and Ide, H. Distinct repair activities of human 7,8-dihydro-8- oxoguanine DNA glycosylase and formainidopyrimidine DNA glycosylase for formamidopyrmidine and 7,8-dihydro-8- oxoguanine. J. Biol. Chem. 2000, 275, 4956-4964
  5. Bielas, J. H., and Heddle, J. A. Proliferation is necessary fcr both repair and mutation in transgenic mouse cells. Proc. Natl. Acad. Sci. USA. 2000, 97, 11391-11396
  6. Ferrera, C. G., Tols, C., and Gaccone, G. p53 and chemosenstvty. Ann. Oncol. 1999, 10, 1011-1021
  7. Jung, Y. D., Mansfield, P. F., Akagi, M., Takeda, A. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur. J. Cancer. 2002, 38, 1133-1140
  8. Finzi, E., Harkins, R., and Horn, J. TGF-a is widely expressed in differentiated as well as hyperproliferative skin epithelium. J Invest. Dermatol. 1991, 96, 328-332
  9. Dixit, M., Yang, J. L., Poirier, M. C., Price, J. 0., Andrews, P. A., and Arteaga, C. L. Abrogation of cisplatin-induced programmed cell death in hman breast cancer cells by epidermal growth factor antisense RNA. J. Natl. Cancer Inst. 1997, 89, 365-373
  10. Roberts, A. B., Lamb, L.C., and Newton, D. L. Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc. Natl. Acad. Sci. USA. 1980, 77, 3494-3498
  11. Eastman, A., and Schulte, N. Enhanced DNA repair as a mechanism of resistance to cis-diamininedichloro-platinum (II). Biochemistry 1998, 27, 4730-4734
  12. Depierre, A., Westeel, V., and Jacoulet, P. New neoadjuvant approaches using gemcitabine in non-small-cell lung cancer. Bull. Cancer. 2002, 89, S76-S79
  13. Hansen, W. K., Deutsch, W. A., Yacoub, A., Xu, Y., Williams, D. A., and Kelley, M. R. Creation of a fully functional human chimeric DNA repair protein. Combining 06-inethy1guanme DNA methyltransferase (MGMT) and AP endonuclease (APE/redox effector factor 11) DNA repair proteins. J. Biol. Chem. 1998, Pharmacol. Exp. Ther. 2002, 303, 753-759
  14. Hansen, W. K., and Kelley, M. R. Review of mammalian DNA repair and translational implications. J. Pharmacol Exp. Ther. 2000, 295, 1-9
  15. Baekelands, M., Kristensen, G. B., Trope, C. G., Nesland, J. M., and Holm, R. E. Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer. Anticancer Res. 1999, 19, 4469-4474
  16. Chan, D. W., Chen, B. P., and Prithivirajsingh, S. Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-stand breaks. Genes Dev. 2002, 16, 2333-2338
  17. Nice, E. C., Domagala, T., Fabri, L., Nerriea, M., Walker, F., Jorissen, R. N., Burgess, A. W., Cui, D. F., and Zhang, Y. S. Rapid microscale enzymic semisynthesis of epidermal growth factor (EGF) analogues. Growth factors 2000, 20, 71-80
  18. Sekiguchi, L, Suzuki, M., Tamada, T., Shinimiya, N., Tsuru, S., and Murata, M. DNA damage induciblegene expression following platinum treatment in human ovarian carcinoma cell lines. Oncology. 1996, 53, 19-26
  19. Kim, C. H., Park, S. J., and Lee, S. H. A Targeted Inhibition of DNA-dependent Protein Kinase Sensitizes Breast Cancer Cells Following Ionizing Radiation. J. Pharmacol. Exp. Ther. 2002, 303, 753-759
  20. Salton, S. R., Ferri, G. L., Hahm, S. VGF: a novel role for this neuronal and neuroendocrine polypeptide in the requlation of energy balance. Front Neuroendocrinol. 2000, 21, 199-219
  21. Lai, G. M., Ozols, R. F., Smyth, J. F., Young, R.,F., and Hamilton, T. C. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem. Pharmacol. 1988, 37, 4597-4600
  22. Ozanne, G. M. Measurement of functional residual capacity during mechanical ventilation by simultaneous exchange of two insoluble gases. Anesthesiology. 1981, 54, 413-417
  23. Witters, L., Kumar, R., Mandal, M., Bennett, C. F., Miraglia, L., and Lipton, A. Antisense oligonucleotides to the epidermal growth factor receptor. Breast Cancer Res. Treat. 1999, 53, 41-50
  24. Nehme, A., Baskaran, R., Aibi, S., Fink, D., Nebel, S., Cenni, B., Wang, J. Y., Howell, S. B., and Christen, R. D. Differential induction of c-jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and deficient cells exposed to cisplatin. Cancer Res. 1997, 57, 3253-3257
  25. Louis, D. N. A molecular genetic model of astrocytona histopathology. Brain Pathol. 1997, 7, 755-764
  26. Derynck, B., Goeddell, D. V., and Ullrich, A. Synthesis of messenger RNAs for transforming growth factor $\alpha$ and $\beta$ and the epidermal growth factor receptor by human tumors. Cancer. 1987, 47, 707-712
  27. De Vita, V. T., Hellman, S., and Rosenberg, S. A. (eds): Cancer: principales and practice of oncology. 5th ed, pp 1502-1539. 1997
  28. Dinapoli, R. P., Brown, L. D., Arusell, R. M., Earle, J. D., O'Fallon , J. R., Buckner, J. C., Scheithauer, B. W., Krook, J. E., Tschetter, L. K., and Maier, J. A. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J. Clin. Oncol. 1993, 11, 1316-1321
  29. Karahalil, B., Girard, P. M., Boiteux, S., and Dizdaroglu, M. Substrate specificity of the Oggl protein of Saccharomyces cerevisiae: Excision of guanine lesions produced in DNA by ionizing radiation- or hydrogen peroxide/metal ion-generated free radicals. Nucleic Acids Res. 1998, 26, 1228-1233
  30. Johnson, S. W., Perez, R. P., Godwin A. K., Yeung, A. T., Handel, L. M., Ozols, R. F., and Hamiltun, T. C. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem. Pharmacol. 1994, 47, 689-697
  31. Crul, M., van Wardenburg, R. C., Beijnen, J. H., and Schellens, J. H. DNA-based drug interactions of dsplatin. Cancer Treat Rev. 2002, 28, 291-303